<![CDATA[Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma]]>

Phase 2positiveepcoritamabbendamustinerituximabPositive

AI Analysis

Summary

Epcoritamab combined with bendamustine and rituximab demonstrated a 96% complete response rate in a phase 1b/2 trial for untreated follicular lymphoma patients, showing sustained clinical benefit.

Clinical Trial Data

Phase

1b/2

Primary Endpoint

Met

Outcome Details

96% complete response rate in untreated follicular lymphoma patients

Importance:7/10

Sentiment:

0.80

oncologylymphomacombination therapyclinical trialcomplete response

Related Companies

$GMAB

Read the original article

Published by Cancer Network on August 7, 2026 3:30 PM

Read Original